- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00919945
Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn
Study Overview
Status
Conditions
Detailed Description
Neonates with critical congenital heart disease (CHD) undergoing surgery often have postoperative decreases in cardiac output. These hemodynamic changes can result in varying levels of organ dysfunction, ranging from the subclinical to the more overt. Although this low cardiac output syndrome (LCOS) and accompanying multiorgan dysfunction syndrome (MODS) is in large part transient, the rapidity and completeness of resolution can vary greatly.
During postoperative care in the intensive care unit, knowledge of this phenomenon must be balanced against the desire to initiate enteral nutrition. Many studies have demonstrated that timely initiation of enteral feeds in the intensive care can reduce mortality, morbidity and costs. Practically speaking, the decision to initiate feeds is made based on the patient's postoperative hemodynamic status, a normal lactate, absence of vasopressor agents and presence of bowel sounds. Trophic enteral feeding can usually commence 24h postoperatively, even after complicated neonatal heart surgery,
The vast majority of postoperative neonates suffer no apparent ill effects from this management strategy. However, recent data have demonstrated an exceedingly high incidence (3.3-6.8%) of necrotizing enterocolitis (NEC) in CHD patients; a disease for which diminution in splanchnic blood flow and disruption of the mucosal barrier are felt to play an important role. These data suggest the combination of diminished cardiovascular reserve, cyanosis and increased myocardial oxygen demands may promote the development of NEC.
Preliminary data from Sickkids (Chanthong and Sivarajan, 2008) demonstrates an NEC incidence of 8% in CHD patients. Patients with NEC also accounted for 25% of all cardiac arrests in Cardiac CCU.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- neonates ≤ 30 days of postnatal age at time of operation
- birthweight > 2.5 kg
- gestational age at birth ≥ 35 weeks
- Patients requiring cardiac surgery who are expected to remain intubated in the CCIU for > 48 hours
- informed consent by parent or guardian
- approval by treating critical care staff physician
Exclusion Criteria:
- patients with heterotaxy or pre-existing renal or abdominal pathology (eg. preoperative diagnosis of NEC).
- need for ECMO after repair within the study period (data up to that point will be recorded and analyzed).
- Parent refusal of formula for purposes of study
- Patient on vasopressin or norepinephrine infusion
- Parent or legal guardian refuse consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1
The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed.
Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms.
Patients in arm 1 will receive continuous nasogastric formula feeding at time 1 and NPO at time 2 (12 hours later).
|
Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)
|
|
Experimental: 2
The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed.
Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms.
Patients in arm 2 will receive NPO at time 1 and crossover to continuous nasogastric formula feeding at time 2.
|
NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in ultrasound derived bloodflow in superior mesenteric artery after feeding by 1 SD from prefeeding value.
Time Frame: At 0, 6, 12 and 24 hours after arrival at CCU; At 12 and 24 hours after decision to feed is made
|
At 0, 6, 12 and 24 hours after arrival at CCU; At 12 and 24 hours after decision to feed is made
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Impact of Feeding on: Cardiac Output as measured by continuous mass spectometry, Fractional splanchnic output, Renal Perfusion, Tonometric, Assessment of gastric mucosal pH e. Cerebral oxygen delivery using the NIRS probe
Time Frame: Duration of patient's participation in the study
|
Duration of patient's participation in the study
|
|
Correlation and Agreement between: Echo and continuous cardiac output measures; gastric tonometry, SMA PSV and qualitative Bowel Perfusion Index; renal artery PSV and temporal urine output
Time Frame: Duration of patient's participation in the study
|
Duration of patient's participation in the study
|
|
Patient Outcomes: Survival, Time to Extubation, Duration of Postop ICU Admission, Duration of Postop hospital Admission, Discharge weight, Number of Nosocomial Infections, Development of NEC
Time Frame: Duration of patient's [articipation in the study
|
Duration of patient's [articipation in the study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ben Sivarajan, MD, The Hospital for Sick Children
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000012584
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Heart Disease
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingAdult Congenital Heart Disease | Congenital Heart Disease (CHD) | Pediatric Congenital Heart Disease | Heart Transplant PatientsItaly
-
Seoul National University HospitalUniversity of SeoulNot yet recruitingCongenital Heart Disease in Children | Congenital Heart Disease (CHD) | Complex Congenital Heart DiseaseKorea, Republic of
-
University of UlsterBelfast Health and Social Care TrustCompletedCongenital Heart Disease | Congenital Heart Defect | Adult Congenital Heart DiseaseUnited Kingdom
-
China National Center for Cardiovascular DiseasesPeking University; Shandong University; Guangxi Medical University; Wenzhou Medical... and other collaboratorsActive, not recruitingStructural Heart Disease | Congenital Heart Disease (CHD)China
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Disease CongenitalUnited States
-
The Children's Hospital of Zhejiang University...Beijing Children's Hospital; Children's Hospital of Nanjing Medical UniversityNot yet recruitingCongenital Heart Disease in Children | Congenital Heart Disease (CHD)China
-
Martin SchweigerUniversity Children's Hospital, ZurichRecruitingFontan Physiology | Congenital Heart Disease in Children | Congenital Heart SurgerySwitzerland
-
University Hospital, BordeauxRecruitingComplex Congenital Heart DiseaseFrance
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruitingAdult Congenital Heart DiseaseItaly
-
YHAlattarNot yet recruitingCritical Congenital Heart Disease
Clinical Trials on Continuous feeding at time 1 and NPO at time 2
-
University of Massachusetts, WorcesterNational Cancer Institute (NCI)Completed
-
Nanfang Hospital, Southern Medical UniversityCompletedNonalcoholic Fatty Liver DiseaseChina
-
Nanfang Hospital of Southern Medical UniversityCompletedNonalcoholic Fatty Liver DiseaseChina
-
The First Affiliated Hospital with Nanjing Medical...UnknownProliferative Diabetic Retinopathy | VEGF OverexpressionChina
-
University of LeicesterSanofi Pasteur, a Sanofi Company; University Hospitals, Leicester; World Health... and other collaboratorsCompletedInfluenza | Influenza -Like IllnessUnited Kingdom
-
Centre Hospitalier Universitaire de Saint EtienneTerminated
-
Mezoo Co., Ltd.CompletedArrhythmias, CardiacKorea, Republic of
-
Avera McKennan Hospital & University Health CenterVintek, LLCCompleted
-
Mezoo Co., Ltd.RecruitingArrhythmias, CardiacKorea, Republic of
-
Nantes University HospitalRecruitingCongenital Heart Defects | Thymectomy | Immunological Deficiency SyndromeFrance